Clearside Biomedical’s Phase IIb ODYSSEY study of its drug-device combination CLS-AX (axitinib injectable suspension) has ...

The global AMD drugs market is set to grow from USD 10.46 billion in 2024 to USD 17.37 billion by 2029, reflecting a robust ...

Ocular Therapeutix's Elutyx drug delivery platform offers sustained long-term effects. See why OCUL stock is a Buy.

Clearside Biomedical reported positive results from a Phase 2b trial of its tyrosine kinase inhibitor in patients with wet ...

SOL-1 is now expected to be enrolled and fully randomized by year-end 2024Topline clinical data from SOL-1 are now expected in Q4 2025BEDFORD, ...

Age-related macular degeneration (AMD) is one of the leading causes of vision loss in adults over 50 in the United States.

Clearside Biomedical today announced that the ODYSSEY study of its drug-device combination achieved its primary and secondary ...

D stock is a contrarian trade opportunity based on the market assumption that the promising Wet Amd eye disease gene therapy ...

ANX007 Demonstrated Significant Vision Protection in Standard and Low Light Conditions and Significant Photoreceptor Preservation in the Fovea ...

Fintel reports that on October 16, 2024, Scotiabank initiated coverage of Ocular Therapeutix (NasdaqGM:OCUL) with a Sector ...

We now introduce an algorithm called Root Causal Strength using Perturbations (RCSP) that discovers the surrogate ancestors of each variable using Perturb-seq and then computes the RCS of each ...

The Exascale Era began in spring 2022 when the Top500 list certified that the HPE-AMD Frontier supercomputer at Oak Ridge ...